Janux Therapeutics, Inc.

NASDAQ:JANX

54.21 (USD) • At close November 7, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q1
Revenue 0.4398.8971.2522.4612.5171.0572.0482.8451.8132.3651.5891.6161.1590.4820.380000
Cost of Revenue 00.5060.5320.5310.50.4710.4530.4030.2490.1080.0810.0648.4064.7371.9250.9850.8340.6730.549
Gross Profit 0.4398.3910.721.932.0170.5861.5952.4421.5642.2571.5081.552-7.247-4.255-1.545-0.985-0.834-0.673-0.549
Gross Profit Ratio 10.9430.5750.7840.8010.5540.7790.8580.8630.9540.9490.96-6.253-8.828-4.0660000
Reseach & Development Expenses 18.61414.89814.0712.24111.89214.92415.86515.43413.73714.08610.18411.1698.4064.7371.9250.9850.8340.6730.549
General & Administrative Expenses 17.6677.8217.3436.3576.4386.8816.4645.6776.0985.544.9473.9373.6561.9970.7390.670.4220.4330.277
Selling & Marketing Expenses 0-0.506-0.5320000000000000000
SG&A 17.6677.3156.8116.3576.4386.8816.4645.6776.0985.544.9473.9373.6561.9970.7390.670.4220.4330.277
Other Expenses 0-14.8980-7.0674.24502.8222.2010000.07400000-1.245-0.49
Operating Expenses 36.28122.21320.88118.59818.3321.80522.32921.11119.83519.62615.13115.10612.0626.7342.6641.6551.2561.1060.826
Operating Income -35.842-13.822-20.161-16.137-15.813-20.748-20.281-18.266-18.022-17.261-13.542-13.49-10.903-6.252-2.284-1.655-1.256-1.106-0.826
Operating Income Ratio -81.645-1.554-16.103-6.557-6.282-19.629-9.903-6.42-9.94-7.299-8.522-8.348-9.407-12.971-6.0110000
Total Other Income Expenses Net 7.7837.8635.4014.3794.2453.242.8222.2011.3260.3730.1320.0740.1370.046000-1.245-0.49
Income Before Tax -28.059-5.959-14.76-11.758-11.568-17.508-17.459-16.065-16.696-16.888-13.41-13.416-10.766-6.206-2.284-1.655-1.256-2.46-1.413
Income Before Tax Ratio -63.916-0.67-11.789-4.778-4.596-16.564-8.525-5.647-9.209-7.141-8.439-8.302-9.289-12.876-6.0110000
Income Tax Expense 000.4890.953-0.50.349-0.453-4.805-2.652-0.373-0.264-0.0740.1370.046000-1.136-0.393
Net Income -28.059-5.959-14.76-11.758-11.568-17.508-17.459-11.26-14.044-16.515-13.146-13.416-10.766-6.206-2.284-1.655-1.256-2.46-1.413
Net Income Ratio -63.916-0.67-11.789-4.778-4.596-16.564-8.525-3.958-7.746-6.983-8.273-8.302-9.289-12.876-6.0110000
EPS -0.51-0.11-0.3-0.25-0.25-0.42-0.42-0.27-0.34-0.4-0.32-0.33-0.26-0.62-0.057-0.13-0.1-0.2-0.11
EPS Diluted -0.51-0.11-0.3-0.25-0.25-0.42-0.42-0.27-0.34-0.4-0.32-0.33-0.26-0.62-0.057-0.13-0.1-0.2-0.11
EBITDA -35.842-13.316-19.629-15.606-15.813-20.277-20.281-18.266-17.773-17.153-13.461-13.49-10.739-6.193-2.275-1.646-1.255-2.35-1.314
EBITDA Ratio -81.645-1.497-15.678-6.341-6.282-19.184-9.903-6.42-9.803-7.253-8.471-8.348-9.266-12.849-5.9870000